WuXi AppTec's 1260H listing impact limited, UBS maintains buy

WuXi AppTec's inclusion on a US military-linked companies list will have negligible financial impact because of minimal exposure to government contracts, UBS said.

The US Defense Department's addition of WuXi AppTec to its Section 1260H list of Chinese military companies will have limited fundamental impact given negligible US government revenue exposure, UBS said.

"WuXi AppTec is not a Chinese military company — not based on an objective review of the facts, and not under the statutory designation criteria for the Section 1260H list under US law," the company said in an open letter to customers, adding it would pursue every available avenue to correct the classification.

The designation, announced June 8, prohibits the Defense Department from directly contracting with listed entities starting June 30, 2026, with a broader ban on goods or services from these companies taking effect June 30, 2027. WuXi AppTec generates about three-quarters of its revenue from the US, but almost entirely from biopharmaceutical and biotechnology companies rather than government agencies, according to RBC Capital Markets. The listing also triggers restrictions under the Biosecure Act, giving US companies with preexisting contracts five years from 2028 to transition away from Chinese providers.

The practical risk is whether customers accelerate supply-chain diversification before the 2033 deadline. UBS said WuXi AppTec's operating momentum remains resilient, supported by strong demand in its TIDES and small-molecule businesses. The company maintained its full-year 2026 guidance for 18 percent to 22 percent growth in continuing operations revenue, with total revenue of 51.3 billion yuan to 53.0 billion yuan, representing year-over-year growth of 12.9 percent to 16.6 percent.

WuXi AppTec was among more than 50 companies added to the list in the Pentagon's largest single update, bringing the total to 188 designated entities. The expanded list also included Alibaba Group, Baidu, BYD, NIO, solar manufacturers JA Solar and Trina Solar, and semiconductor firms CXMT and YMTC. The Pentagon cited affiliations with China's State-owned Assets Supervision and Administration Commission and the Ministry of Industry and Information Technology as factors in the designations.

Chinese technology companies without military backgrounds have successfully challenged 1260H designations before. Xiaomi was removed from the list in 2021 and AMEC in 2024 after demonstrating a lack of factual and legal basis for the administrative decisions, UBS noted. WuXi AppTec has already initiated legal proceedings to challenge its inclusion.

WuXi AppTec has supported the development of eight of the 30 small-molecule drugs approved by the US Food and Drug Administration in 2025, according to a company presentation at the J.P. Morgan Healthcare Conference. Any disruption to its US operations could create opportunities for European and North American competitors such as Bachem, PolyPeptide Group, Charles River Laboratories, and Evotec, according to RBC Capital Markets.

WuXi AppTec shares traded at HKD121.80 on Thursday, up 1.16 percent, with turnover of HKD456 million. The stock trades at 17 times its 2026 forecast earnings. UBS set a target price of HKD171.20 for the H-shares, implying about 40 percent upside, and reiterated a Buy rating.

This article is for informational purposes only and does not constitute investment advice.